New Advances in Nano-Drug Delivery Systems: Helicobacter pylori and Gastric Cancer

Abstract

With the development of materials science and biomedicine, the application of nanomaterials in the medical field is further promoted. In the process of the diagnosis and treatment of diseases, a variety of drugs need to be used. It is an ideal state to make these drugs arrive at a specific location at a specific time and release at a specific speed, which can improve the bioavailability of drugs and reduce the adverse effects of drugs on normal tissues. Traditional drug delivery methods such as tablets, capsules, syrups, and ointments have certain limitations. The emergence of a new nano-drug delivery system further improves the accuracy of drug delivery and the efficacy of drugs. It is well known that the development of the cancer of the stomach is the most serious consequence for the infection of Helicobacter pylori. For the patients who are suffering from gastric cancer, the treatments are mainly surgery, chemotherapy, targeted and immune therapy, and other comprehensive treatments. Although great progress has been made, the diagnosis and prognosis of gastric cancer are still poor with patients usually diagnosed with cancer at an advanced stage. Current treatments are of limited benefits for patients, resulting in a poor 5-year survival rate. Nanomaterials may play a critical role in early diagnosis. A nano-drug delivery system can significantly improve the chemotherapy, targeted therapy, and immunotherapy of advanced gastric cancer, reduce the side effects of the original treatment plan and provide patients with better benefits. It is a promising treatment for gastric cancer. This article introduces the application of nanomaterials in the diagnosis and treatment of H. pylori and gastric cancer.

Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections

“…Curcumin in combined therapy had synergistic effects and caused a more significant H. pylori reduction effect (Ranjbar and Mohammadi 2018 ). Nanocarriers could protect antibiotics in harsh gastric environments (Zhu et al 2022 ). As for the treatment for H. pylori , oral drug nanocarriers own advantages in dealing with the harsh acidified environment in the stomach and the hard to reach residence site of the pathogen (Zhang et al 2020 ).…”

Natural products targeting signaling pathways associated with regulated cell death in gastric cancer: Recent advances and perspectives

“…In the case of natural drugs, many factors limit its basic research and clinical transformation. In preclinical studies, various natural agents failed due to its poor bioavailability or activity, which could be solved by modifying their structures or dosage form (Roviello et al, 2019; Zhu, Su, et al, 2022a). Previous clinical evidence has demonstrated that few natural compounds triggered apoptosis of GC cells in patients, such as paclitaxel, camptothecin, colchicine, and ginsenoside Rg3.…”

Treatment of H. pylori infection and gastric ulcer: Need for novel Pharmaceutical formulation

“…Drug-loaded NPs achieve their therapeutic effect via localized accumulation and sustained release. This postulates that the nanoparticle-based formulation of antibiotics is a good option for treating H. pylori [ [163] , [164] , [165] ]. Furthermore, when compared to direct antibiotic use, nanoparticular systems have imparted less toxicity in therapy, and these strategies play critical part in reducing antibiotic resistance.…”